multiple%20myeloma
MULTIPLE MYELOMA

Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion.

It accounts for 1-2% of all cancers worldwide & mostly affects patients at ages 65-74 years old.

Patient usually presents with bone pain & nonspecific symptoms, or due to abnormalities in laboratory exams.

 

Drug Information

Indication: Acute leukemia. In combination w/ other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphom...

Indication: RA, acute gouty arthritis, bronchial asthma, serum sickness, lupus, nodular arthritis, allergic dermatitis, pe...

Indication: Breast, gastric, ovarian & small cell lung cancer; non-Hodgkin's lymphoma; advanced/metastatic soft tissue...

Indication: Anaemia associated w/ chronic renal failure in haemo- & predialysis adults & haemodialysis paed. Facil...

Indication: Replacement therapy in primary immunodeficiency syndromes eg, congenital agammaglobulinaemia & hypogammagl...

Indication: Primary humoral immunodeficiency. Idiopathic thrombocytopenic purpura. Chronic inflammatory demyelinating poly...

Indication: In combination w/ dexamethasone or lenalidomide + dexamethasone for patients w/ relapsed or refractory multipl...

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum based chemother...

Indication: Conditions associated w/ increased osteoclast activity eg, predominantly lytic bone metastases from breast can...

Indication: Breast, gastric, ovarian, small cell lung & superficial bladder (Tis, Ta) cancer, Non-Hodgkin's lymphoma, ...

2  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
10 Mar 2017
The addition of pravastatin to standard chemotherapy does not improve outcomes in patients with small-cell lung cancer (SCLC), results of a study have shown.
Tristan Manalac, 03 Dec 2019
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.